Retrospective analysis of predictive factors for pathological complete response after neoadjuvant chemotherapy in gastric cancer

Figure 2 Comparison of pathological complete response rates among different neoadjuvant chemotherapy approaches in gastric cancer. This figure compares pathological complete response rates in gastric cancer patients receiving neoadjuvant chemotherapy, demonstrating that fluorouracil, leucovorin, oxaliplatin, docetaxel regimen, oxaliplatin-containing compounds, and ≥ 4 chemotherapy cycles achieved significantly higher pathological complete response rates (P < 0.05) than their counterparts. The results highlight key factors that may optimize pathological complete response in gastric cancer treatment, with fluorouracil, leucovorin, oxaliplatin, docetaxel showing the highest response rate (27.5%) among all evaluated regimens. P value was shown as a P < 0.05. FLOT: Fluorouracil, leucovorin, oxaliplatin, docetaxel; SOX: S-1, oxaliplatin; XELOX: Capecitabine, oxaliplatin; DCF: Docetaxel, cisplatin, fluorouracil; CI: Confidence interval; pCR: Pathological complete response.